Avastin® (bevacizumab) – Expanded Indication
December 6, 2016 – Genentech announced the FDA approval of Avastin (bevacizumab) injection, in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Top